Doubts using family history, age, alpha-fetoprotein and total human chorionic gonadotrophin in screening for Down's syndrome.

Recent advances. Obstetrics. BMJ (1995) 2.35

Doubts using family history, age, alpha-fetoprotein and total human chorionic gonadotrophin in screening for Down's syndrome. Br J Obstet Gynaecol (1995) 0.75

Kidney transplantation under FK 506. JAMA (1990) 7.45

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol (2001) 2.76

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Characterization of influenza virus RNA complete transcripts. Virology (1982) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Influenza virus RNA segment 7 has the coding capacity for two polypeptides. Virology (1980) 1.80

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Nucleotide sequences at the terminal of La Crosse virus RNAs. Nucleic Acids Res (1980) 1.61

New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56

Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology (2005) 1.56

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A (1999) 1.54

An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant (2001) 1.48

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis (1995) 1.28

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant (1994) 1.15

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation (1999) 1.14

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

Tacrolimus in renal transplantation. Transplant Proc (1996) 1.10

An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol (1993) 1.09

The spectrum of ciclosporin nephrotoxicity. Am J Nephrol (1990) 1.05

FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol (1993) 1.02

Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation (1999) 1.00

Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc (1997) 0.98

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant (2008) 0.98

Structure and synthesis of influenza virus complementary RNAs. Philos Trans R Soc Lond B Biol Sci (1980) 0.97

Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation (1999) 0.96

Interferon-alpha-induced acute renal allograft rejection. Transplantation (1995) 0.95

Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation (1997) 0.95

Listeriosis in mother and fetus during the first trimester of pregnancy. Case report. Br J Obstet Gynaecol (1984) 0.93

Acute cellular rejection with CD20-positive lymphoid clusters in kidney transplant patients following lymphocyte depletion. Am J Transplant (2007) 0.92

Toluidine blue in the corroboration of rape in the adult victim. Am J Emerg Med (1987) 0.91

Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc (1998) 0.91

Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? Transplantation (2000) 0.91

Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant (1997) 0.90

PORCN gene mutations and the protean nature of focal dermal hypoplasia. Br J Dermatol (2009) 0.90

Toluidine blue in the detection of perineal lacerations in pediatric and adolescent sexual abuse victims. Pediatrics (1986) 0.90

Methods for the detection of non-random base substitution in virus genes: models of synonymous nucleotide substitution in picornavirus genes. Virus Genes (1998) 0.89

Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transplant Proc (2005) 0.88

Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc (1991) 0.87

Relationship of cytoskeletal filaments to annular gap junction expression in human adrenal cortical tumor cells in culture. Exp Cell Res (1997) 0.86

Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc (2005) 0.86

Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc (1993) 0.85

Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol (1994) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol (1995) 0.85

Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol (1999) 0.84

Proteinuria in pre-eclampsia. J Obstet Gynaecol Br Commonw (1973) 0.84

Tacrolimus nephrotoxicity after renal transplantation. Transplant Proc (1997) 0.83

"Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation (1996) 0.82

Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation (1999) 0.82

Reducing the length of stay after kidney transplantation--the intensive outpatient unit. Clin Transplant (1998) 0.82

A critical evaluation of renal protein selectivity in pregnancy. J Obstet Gynaecol Br Commonw (1974) 0.82

Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc (1998) 0.81

Cancer risk with alemtuzumab following kidney transplantation. Clin Transplant (2013) 0.81

Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. Transplant Proc (1991) 0.81

FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc (1991) 0.80

Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther Drug Monit (1996) 0.80

Influenza virus haemagglutinin signal sequence. FEBS Lett (1979) 0.80

Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc (1997) 0.79

Vitamin K deficiency with hemorrhage after kidney and combined kidney-pancreas transplantation. Am J Kidney Dis (1999) 0.79

Family awareness demonstrated by family practice residents: physician behavior and patient opinions. J Fam Pract (1985) 0.79

Two-year experience with FK 506 in pediatric patients. Transplant Proc (1993) 0.78

In vitro effects of cyclosporine and FK 506 on the renal cortex. Transplant Proc (1991) 0.78

Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. Transplant Proc (1996) 0.78

Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. Transplant Proc (1999) 0.78

FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc (1993) 0.77

The effect of potassium ion depletion on postinfarction canine cardiac arrhythmias. Circulation (1988) 0.77

Quantitative analysis of 23-valent 'Pneumovax' by automated rate nephelometry. J Biol Stand (1984) 0.77

Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc (2001) 0.76

Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. Transplant Proc (1995) 0.76

Percutaneous transluminal renal angioplasty in nonatherosclerotic renovascular hypertension. Long-term results. Hypertension (1985) 0.75

Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc (2001) 0.75

Alopecia as a consequence of tacrolimus therapy. Transplantation (1998) 0.75

A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc (2002) 0.75

Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc (1997) 0.75

Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc (1993) 0.75

A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. Transplant Proc (1991) 0.75

A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol (1998) 0.75

Effect of recipient race on waiting time for renal transplantation at the University of Pittsburgh. Transplant Proc (1993) 0.75

Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplant Proc (1995) 0.75

Outcome of kidney transplantation in African-Americans using tacrolimus. Transplant Proc (1997) 0.75

Posttransplant hypertension in blacks versus nonblacks. Transplant Proc (1993) 0.75

Laboratory preparedness in EU/EEA countries for detection of novel avian influenza A(H7N9) virus, May 2013. Euro Surveill (2014) 0.75

A tuberculosis outbreak in a renal transplant program. Transplant Proc (1991) 0.75

[Clinical experience with FK 506]. Presse Med (1991) 0.75

Bilateral occlusion of the subclavian veins due to chronic indwelling subclavian catheters. Mil Med (1987) 0.75

Computer-guided concentration-controlled trials in autoimmune disorders. Ther Drug Monit (1993) 0.75

Superior vena cava syndrome due to subclavian hemodialysis catheters. Mil Med (1990) 0.75

A spectroscopic investigation of losartan polymorphs. Pharm Res (1993) 0.75

FK 506 interaction with danazol. Lancet (1993) 0.75

Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord (1999) 0.75